Because of a lapse in government funding, the information on this website may not be up to date transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

NCI Dictionary of Cancer Terms

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Dictionary of Cancer Terms features 8,214 terms related to cancer and medicine.

We offer a widget that you can add to your website to let users look up cancer-related terms. Get NCI’s Dictionary of Cancer Terms Widget.

Browse:
ado-trastuzumab emtansine
(A-doh-tras-TOO-zoo-mab em-TAN-seen)
A drug used to treat HER2-positive breast cancer that has spread to other parts of the body. It is used in patients who have already been treated with the anticancer drug called trastuzumab and a type of drug called a taxane. It may also be used in patients whose cancer has recurred (come back) after adjuvant therapy with these drugs. It is also being studied in the treatment of other types of cancer. Ado-trastuzumab emtansine contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some breast cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells. Ado-trastuzumab emtansine is a type of antibody-drug conjugate. Also called Kadcyla and T-DM1.